Regen BioPharma
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4700 Spring St Ste 304, La Mesa, Califor...Phone Number
(619) 722-5505Website
www.regenbiopharmainc.comRevenue
<$5 MillionStock Symbol
RGBPIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Regen BioPharma
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regen BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Regen BioPharma has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Regen BioPharma recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Regen BioPharma
Product Launch: Get notified when Regen BioPharma launches new products
Check if Regen BioPharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Regen BioPharma is spiking on competitors!
Regen BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Regen BioPharma had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Regen BioPharma as Masked Content
Find more new buyers
Compare Similar Companies to Regen BioPharma
Compare insights from companies similar to Regen BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Regen BioPharma
<$5M
1-10
Public
<$5M
2012
N/A
Company Profile Activity
Activity Insights
Regen BioPharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Regen BioPharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Regen BioPharma.
Regen BioPharma financials insights
Gather financial insights about Regen BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Debt
$13K
Regen BioPharma Tech Stack
A closer look at the technologies used by Regen BioPharma
Most Recent Scoops
Project
Regen BioPharma has submitted final documents to the FDA in response to questions raised about its orphan drug application. The company expects to receive another comment letter as part of the normal process.
Pharmaceuticals, Clinical Operations
Pain Point
Regen BioPharma has experienced delays in advancing to clinical trials due to the need to redo audits for 2023-2024. The company was required to bring an outstanding registration statement current and file for alternative reporting, leading to a decision to remain current with the SEC for better financing opportunities.
Accounting, Compliance, Financial Reporting, Clinical Operations, Finance
Pain Point
Regen BioPharma has reported that despite having 18 impressive patents with potential to revolutionize the medical field, has faced setbacks in financing clinical trials due to SEC restrictions. The company believes it needs to progress through phase one and possibly part of phase two trials before attracting potential acquirers.
Mergers & Acquisitions, Funding, Intellectual Property, Legal Affairs, Acquisitions, Clinical Operations, Finance, Mergers
Pain Point
Regen BioPharma has not raised any money for clinical trials at present, as it had to return previously raised funds due to SEC comments about the company's reporting status.
Funding, Compliance, Clinical Operations, Finance
Project
Medical Research, Pharmaceuticals, Clinical Operations
Regen BioPharma News & Media
Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) today announced the Company is in the process of addressing comments received by the U.S. Food and Drug Administration (FDA) in connection with the Company’s recent submission of an Orphan Drug Application (ODA) to the FDA for HemaXellerate, its lead therapeutic candidate for the treatment of aplastic anemia. Aplastic anemia is a rare and potentially life-threatening boneRegen BioPharma Explores Expanded Use of HemaXellerate for Chemotherapy-Induced Bone Marrow Suppression
Regen’s Approach Could Be Paradigm Shift in Supportive Oncology CareRegen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.Regen BioPharma, Inc. to Seek Orphan Drug Designation for Lead Product
An Orphan Drug Designation Could Provide Significant Benefits to Regen
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Regen BioPharma
Sign Up For FreeTo access detailed company insights
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for tre... Read More
